Loading…
Voyager Therapeutics, Inc. is projected to decline to $3.39 by 2027, a -2% move from its current price of $3.44. VYGR is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 14 | $3.34 | $3.44 | $3.54 | +0.05% |
| Jul 15 | $3.31 | $3.44 | $3.59 | +0.11% |
| Jul 16 | $3.28 | $3.45 | $3.62 | +0.16% |
| Jul 17 | $3.26 | $3.45 | $3.65 | +0.22% |
| Jul 18 | $3.23 | $3.45 | $3.68 | +0.27% |
| Jul 19 | $3.22 | $3.45 | $3.70 | +0.33% |
| Jul 20 | $3.20 | $3.45 | $3.73 | +0.38% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $3.20 | $3.45 | $3.73 | +0.38% |
| Week 2 | $3.11 | $3.47 | $3.86 | +0.77% |
| Week 3 | $3.05 | $3.48 | $3.97 | +1.15% |
| Week 4 | $3.00 | $3.49 | $4.07 | +1.54% |
| Week 5 | $2.96 | $3.51 | $4.16 | +1.93% |
| Week 6 | $2.92 | $3.52 | $4.24 | +2.31% |
| Week 7 | $2.89 | $3.53 | $4.32 | +2.71% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases.
Its product pipeline includes VY1706, a tau silencing gene therapy and VY7523, an anti-tau antibody program for the treatment of Alzheimer's disease. The company also provides research program for the treatment of Huntington's disease. In addition, it offers TRACER, an adeno-associated virus (AAV) capsid discovery platform; ALPL-VYGR-NeuroShuttle, to target an undisclosed neurological disease; and develops selective small molecules for the treatment of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia with TDP-43 pathology.
The company has collaboration and license agreements with Alexion; AstraZeneca Ireland Limited; Novartis Pharma AG; and Transition Bio, Inc. for the treatment of various other diseases of the central nervous system. Voyager Therapeutics, Inc.
was incorporated in 2013 and is headquartered in Lexington, Massachusetts.
Voyager Therapeutics, Inc. trades under the symbol VYGR in the Healthcare sector. The current price is $3.63 and the market capitalization stands at $219.33M, with a rank of 3759.
The stock’s current price, relative to key moving averages, places it around recent trading levels. The forecast landscape shows a path of growth across multiple years, with gradual upside in the near term and substantial gains projected further out, culminating in a max price forecast of $36.95 by 2050 and a max ROI of 426.8%.
Today’s entries include a 30-day technical backdrop that supports a cautious outlook near-term, while the multi-year projections point to a bullish longer-term trajectory, albeit with inherent uncertainty.
A major floor 13.6% below — a decisive break under it would weaken the trend.
The nearest floor, 3.5% below — buyers have tended to step in here.
The nearest ceiling, 13.4% above — a clean break opens room to run.
A major ceiling 45.3% above — clearing it would confirm fresh momentum.
Key VYGR support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of VYGR market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $3.65 | Sell | $3.61 | Sell |
| MA 10 | $3.63 | Sell | $3.63 | Sell |
| MA 20 | $3.62 | Sell | $3.63 | Sell |
| MA 50 | $3.71 | Sell | $3.70 | Sell |
| MA 100 | $3.85 | Sell | $3.80 | Sell |
| MA 200 | $4.05 | Sell | $3.94 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 42.24 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | -144.03 | Sell |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | 0.00 | Buy |
| ROC (12) | -7.03 | Sell |
| Bollinger %B (20,2) | 0.05 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | -0.08 | Sell |
| Awesome (5,34) | 0.02 | Buy |
| Ultimate (7,14,28) | 43.79 | Neutral |
| Momentum (10) | -0.11 | Sell |
| Aroon Osc (25) | 68.00 | Buy |
| Hull MA (9) | 3.66 | Sell |
| ADX (14) | 9.16 | Neutral |
| ATR (14) | 0.10 | Info |
The 30-day technical picture is BEARISH. RSI(14) is 50, with the 50-day simple moving average at $3.82 and the 200-day simple moving average at $4.09. Support is noted at $3.32 and resistance at $4.24. The 30-day trading range spans from $2.97 to $4.44.
Overall near-term sentiment remains subdued while price action hovers around the mid-range of these levels, suggesting potential for a test of the support or resistance depending on momentum in coming weeks.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $3.32 | $3.44 | $4.57 | 0% | Neutral | |
| $2.68 | $3.39 | $4.53 | -2% | Neutral | |
| $2.93 | $3.81 | $5.30 | +11% | Neutral | |
| $3.42 | $4.56 | $6.53 | +33% | Bullish | |
| $3.51 | $4.78 | $7.02 | +39% | Bullish | |
| $3.81 | $5.29 | $7.94 | +54% | Bullish | |
| $3.81 | $5.39 | $8.26 | +57% | Bullish | |
| $3.57 | $5.13 | $8.00 | +49% | Bullish | |
| $3.75 | $5.49 | $8.70 | +59% | Bullish | |
| $4.22 | $6.27 | $10.09 | +82% | Bullish | |
| $4.97 | $7.93 | $13.62 | +131% | Bullish | |
| $8.97 | $16.21 | $30.54 | +371% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $3.32 | $3.44 | $4.18 | +0.00% |
| August 2026 | $3.08 | $3.64 | $4.42 | +5.87% |
| September 2026 | $3.04 | $3.62 | $4.44 | -0.73% |
| October 2026 | $2.94 | $3.52 | $4.37 | -2.59% |
| November 2026 | $2.97 | $3.58 | $4.48 | +1.61% |
| December 2026 | $3.00 | $3.63 | $4.57 | +1.40% |
Click any year to see its month-by-month VYGR forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect VYGR to range from $3.32 to $4.57 through 2026. The $3.44 average target implies a 0% move from current prices. A consolidation phase looks the most probable path here.
The VYGR price prediction for 2027 points to an average of $3.39 (low $2.68, high $4.53) — a potential decline of -2% on today's $3.44. Price action looks broadly range-bound.
In 2028, VYGR is projected to trade between $2.93 and $5.30, averaging $3.81 — a potential gain of +11% from today's $3.44. That is up +13% on the projected 2027 average. A consolidation phase looks the most probable path here.
Voyager Therapeutics, Inc.'s 2029 outlook centres on $4.56, within a $3.42 to $6.53 range. That is up +20% on the projected 2028 average. That marks a +33% change versus current levels. Momentum favours further upside here.
By 2030, VYGR could reach as high as $7.02, with a base case around $4.78 and support toward $3.51 — roughly +39% from $3.44. Buyers look set to stay in control over this stretch.
Expect VYGR to range from $3.81 to $7.94 through 2031. The $5.29 average target implies a +54% move from current prices. That is up +11% on the projected 2030 average. Momentum favours further upside here.
The VYGR price prediction for 2032 points to an average of $5.39 (low $3.81, high $8.26) — a potential gain of +57% on today's $3.44. Buyers look set to stay in control over this stretch.
In 2033, VYGR is projected to trade between $3.57 and $8.00, averaging $5.13 — a potential gain of +49% from today's $3.44. That is -5% versus the projected 2032 average. Momentum favours further upside here.
Voyager Therapeutics, Inc.'s 2034 outlook centres on $5.49, within a $3.75 to $8.70 range. That is up +7% on the projected 2033 average. That marks a +59% change versus current levels. Buyers look set to stay in control over this stretch.
By 2035, VYGR could reach as high as $10.09, with a base case around $6.27 and support toward $4.22 — roughly +82% from $3.44. Momentum favours further upside here.
Expect VYGR to range from $4.97 to $13.62 through 2040. The $7.93 average target implies a +131% move from current prices. That is up +27% on the projected 2035 average. Buyers look set to stay in control over this stretch.
The VYGR price prediction for 2050 points to an average of $16.21 (low $8.97, high $30.54) — a potential gain of +371% on today's $3.44. Momentum favours further upside here.
Investing $1,000 in VYGR today (≈ 290.697674 VYGR) could be worth
$4,713.28
+$3,713.28 (+371%) by 2050 · US Dollar
Based on the average projected VYGR price of $16.21 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in VYGRwould be worth at today's price.
$1,000 invested in VYGR on Jul 10, 2025 (≈ 281.690145 VYGR) would be worth
$969.01
-$30.99 (-3.1%) today · 0.97× · US Dollar
Based on a VYGR entry price of $3.55 vs. today's $3.44.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $3.78 | $910.05 | -9.0% |
| 1 month ago | $3.32 | $1,036.14 | +3.6% |
| 3 months ago | $3.74 | $919.79 | -8.0% |
| 6 months ago | $3.9 | $882.05 | -11.8% |
| 1 year ago | $3.55 | $969.01 | -3.1% |
| All time (5.0y) ago | $3.5 | $982.86 | -1.7% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our VYGR forecast.
Our base-case forecast reaches $6.90 around 2040.
Implied market cap at $6.90: $416.91M
The multi-year forecast shows a bullish tilt beginning in the 2029–2030 window and continuing through 2050. For 2026 the avg price is $3.63 with a max of $4.81 and ROI of 0%; by 2027 the avg rises to $3.69 (min $2.90, max $5.00) with ROI 1.7%. In 2028 the avg is $4.31 (min $3.28, max $6.07) and ROI 18.6%.
From 2029 onward, the outlook strengthens: 2029 avg $5.08 (min $3.77, max $7.38), ROI 39.9%; 2030 avg $5.40 (min $3.91, max $8.05), ROI 48.7%; 2031 avg $6.16 (min $4.37, max $9.40), ROI 69.6%; 2032 avg $6.03 (min $4.19, max $9.40), ROI 66.1%; 2033 avg $5.76 (min $3.93, max $9.14), ROI 58.5%; 2034 avg $6.55 (min $4.39, max $10.59), ROI 80.5%; 2035 avg $7.43 (min $4.90, max $12.19), ROI 104.6%.
In the longer horizon, 2040 shows avg $9.77 with ROI 169.2%; and by 2050, avg $19.12 with ROI 426.8%, with a max forecast of $36.95. These figures imply meaningful upside in later years, albeit with significant variability and risk inherent to equities and biotechnology names.
Tap a question to reveal the answer.
Avg $5.40, min $3.91, max $8.05, ROI 48.7%, sentiment BULLISH.
The forecast shows growth with 2030 avg $5.40 and 2050 avg $19.12, plus a max ROI of 426.8%. However, current sentiment varies year by year, and these are estimates, not guarantees.
The 2050 forecast lists an avg of $19.12 and a max of $36.95 with ROI 426.8%, indicating a potential approach to or beyond $20 in a bullish scenario but not a guaranteed outcome.
$2.97 to $4.44.
Current price is $3.63 and market cap is $219.33M; the rank is 3759.
Voyager Therapeutics, Inc. Community Discussion
0Share your Voyager Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.